Details of Disease

General Information of Disease (ID: DIS6GOC8)

• Disease Name: Intrahepatic cholangiocarcinoma
• Synonyms: IHCH; peripheral cholangiocarcinoma; intrahepatic cholangiocarcinoma (bile duct cancer); intrahepatic cholangiocarcinoma; intrahepatic carcinoma of the bile duct; intrahepatic carcinoma of bile duct; intrahepatic bile duct carcinoma; intrahepatic bile duct cancer (cholangiocarcinoma); intrahepatic Cholangiocellular carcinoma; cholangiocarcinoma, intrahepatic, malignant; ICC
• Disease Class: 2C12: Liver cancer
• Definition: A carcinoma that arises from the intrahepatic bile duct epithelium in any site of the intrahepatic biliary tree. Grossly, the malignant lesions are solid, nodular, and grayish. Morphologically, the vast majority of cases are adenocarcinomas. Signs and symptoms include malaise, weight loss, right upper quadrant abdominal pain, and night sweats. Early detection is difficult and the prognosis is generally poor.
• Disease Hierarchy:
  DIS7TSHL: Intrahepatic bile duct cancer
  DIS71F6X: Cholangiocarcinoma
  DIS6GOC8: Intrahepatic cholangiocarcinoma
• ICD Code:
  ICD-11: ICD-11: 2C12.10
  ICD-10: ICD-10: C22.1
  ICD-9: ICD-9: 155.1, 156.1
  Expand ICD-11: '2C12.10
  Expand ICD-10: 'C22.1
  Expand ICD-9: 155.1,156.1
• Disease Identifiers:
  MONDO ID: MONDO_0003210
  MESH ID: D018281
  UMLS CUI: C0345905
  MedGen ID: 87521
  SNOMED CT ID: 109842005

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Futibatinib	DMWM4D0	Approved	NA	[1]
Melphalan	DMOLNHF	Approved	Small molecular drug	[2]

This Disease is Treated as An Indication in 2 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ARQ-087	DM02BVQ	Phase 3	NA	[2]
MUC-1 CART cell immunotherapy	DMFUDHM	Phase 1/2	CAR T Cell Therapy	[3]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 56 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
MSLN	TT4RXME	Limited	Biomarker	[4]
NOS2	TTF10I9	Limited	Biomarker	[5]
PRKACA	TT5U49F	Limited	Biomarker	[6]
SLC5A5	TTW7HI9	Limited	Biomarker	[7]
ANO1	TTOJI4S	moderate	Biomarker	[8]
CEACAM3	TTPX7I5	moderate	Biomarker	[9]
CPS1	TT42M75	moderate	Altered Expression	[10]
GLUL	TTURQ2G	moderate	Biomarker	[11]
GPC3	TTJTSX4	moderate	Altered Expression	[12]
HSPA9	TTMTPG3	moderate	Altered Expression	[13]
L1CAM	TTC9D3K	moderate	Biomarker	[14]
NUAK1	TT65FL0	moderate	Altered Expression	[15]
PDXP	TT9UYG4	moderate	Biomarker	[16]
PMEL	TT8MK59	moderate	Biomarker	[17]
PSMD10	TT2H4LN	moderate	Altered Expression	[18]
PTK7	TTXH2ZN	moderate	Altered Expression	[19]
ROBO1	TTND1YP	moderate	Genetic Variation	[20]
TFF1	TTNOJIZ	moderate	Genetic Variation	[21]
VEGFC	TT0QUFV	moderate	Altered Expression	[22]
AFP	TTCFEA1	Strong	Biomarker	[23]
ANXA10	TT0NL6U	Strong	Biomarker	[24]
ARAF	TT5TURO	Strong	Genetic Variation	[25]
ASPH	TT2KHP7	Strong	Biomarker	[26]
BAP1	TT47RXJ	Strong	Genetic Variation	[27]
CBLB	TTHRAIJ	Strong	Altered Expression	[28]
CEACAM5	TTY6DTE	Strong	Altered Expression	[29]
CLDN18	TT6PKBX	Strong	Altered Expression	[30]
EGFR	TTGKNB4	Strong	Biomarker	[31]
ERBB2	TTR5TV4	Strong	Genetic Variation	[32]
FABP5	TTNT2S6	Strong	Biomarker	[33]
FGFR2	TTGJVQM	Strong	Genetic Variation	[34]
FGFR4	TT1KX2S	Strong	Altered Expression	[35]
GNE	TT4DP5S	Strong	Genetic Variation	[36]
HDAC8	TTT6LFV	Strong	Altered Expression	[37]
IL12RB2	TT4SWR8	Strong	Biomarker	[38]
IMP3	TTEJA2R	Strong	Biomarker	[39]
KAT6A	TT6O1J0	Strong	Genetic Variation	[40]
KCNN3	TT9JH25	Strong	Genetic Variation	[41]
KIR2DL2	TTU0P73	Strong	Biomarker	[42]
KIR2DL3	TTEX3SI	Strong	Biomarker	[42]
KRT19	TT3JF9E	Strong	Biomarker	[43]
MAPK12	TTYT93M	Strong	Biomarker	[44]
NEK8	TT8AH9I	Strong	Biomarker	[45]
PBRM1	TTH8ZRL	Strong	Genetic Variation	[27]
PCSK7	TTD30LY	Strong	Altered Expression	[46]
PRSS1	TT2WR1T	Strong	Biomarker	[47]
PTEN	TTXJ3W7	Strong	Altered Expression	[48]
PTP4A1	TTA8GFO	Strong	Biomarker	[49]
PTPN14	TTNIR6C	Strong	Biomarker	[50]
RBP5	TTV2DON	Strong	Biomarker	[51]
REG4	TTVZEHU	Strong	Biomarker	[52]
RNF43	TTD91BL	Strong	Genetic Variation	[53]
SLC29A1	TTLXAKE	Strong	Biomarker	[54]
STYK1	TTRMCYJ	Strong	Biomarker	[55]
TP53	TT12KOD	Strong	Biomarker	[56]
USP14	TTVSYP9	Strong	Altered Expression	[57]

This Disease Is Related to 4 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CYP7A1	DEDZRQ1	moderate	Biomarker	[35]
UGDH	DE48Q2Z	Strong	Biomarker	[58]
UGT2B11	DE7TIN4	Strong	Altered Expression	[59]
ME1	DE97WM8	Definitive	Biomarker	[60]

This Disease Is Related to 90 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
FCGBP	OT63T6XQ	Limited	Biomarker	[61]
H2AZ1	OT3KJJNQ	Limited	Biomarker	[62]
KMT2C	OTC59BCO	Limited	Biomarker	[63]
PEG3	OTHQW98S	Limited	Biomarker	[63]
ROBO2	OTFJ9FQW	Limited	Biomarker	[63]
AZIN2	OT8OB7CG	moderate	Biomarker	[64]
CDX2	OTCG4TSY	moderate	Biomarker	[31]
CEACAM7	OTKFDTZY	moderate	Biomarker	[9]
CHD1L	OT7CZK7C	moderate	Biomarker	[65]
CXCL5	OTZOUPCA	moderate	Altered Expression	[66]
GADL1	OTJM4A0R	moderate	Biomarker	[64]
MUC2	OT3X4QVX	moderate	Biomarker	[31]
PSG2	OT2EIXAI	moderate	Biomarker	[9]
PTPN3	OTSLZBVY	moderate	Genetic Variation	[67]
S100A11	OTI57KDN	moderate	Biomarker	[68]
STIL	OT9799VN	moderate	Biomarker	[17]
ADGRE2	OTUYJVYG	Strong	Altered Expression	[69]
ADGRE5	OTTSB84Q	Strong	Altered Expression	[69]
ADRM1	OTOU4EY6	Strong	Altered Expression	[70]
AGR3	OTONJPDP	Strong	Altered Expression	[71]
ARID1A	OTRWDV3P	Strong	Biomarker	[72]
AZU1	OTHXU264	Strong	Biomarker	[73]
C15orf48	OT85J32K	Strong	Biomarker	[74]
CA10	OTC3N1F6	Strong	Biomarker	[75]
CAPNS1	OT95EBBD	Strong	Altered Expression	[76]
CRYL1	OT0SJSJM	Strong	Biomarker	[58]
CUL4A	OTTBV70J	Strong	Altered Expression	[77]
DLEC1	OTMKKBUW	Strong	Posttranslational Modification	[78]
EBAG9	OTTQLQCP	Strong	Altered Expression	[79]
EEF1A2	OT9Z23K5	Strong	Altered Expression	[80]
EYA4	OTINGR3Z	Strong	Altered Expression	[81]
FBLN1	OT5MHHOP	Strong	Altered Expression	[82]
GAB1	OTQKE6V4	Strong	Biomarker	[83]
GEMIN2	OT4L6TLL	Strong	Altered Expression	[84]
GINS2	OT974IYI	Strong	Altered Expression	[85]
GLUD1	OTXKOCUH	Strong	Biomarker	[58]
GNAS	OTMH8BKJ	Strong	Biomarker	[86]
H6PD	OTO7TNDD	Strong	Biomarker	[58]
HDLBP	OTKDEEYX	Strong	Biomarker	[73]
HEBP1	OTR9MPDX	Strong	Biomarker	[73]
HGD	OTTKLQOO	Strong	Biomarker	[87]
HHLA2	OTYBTVQS	Strong	Altered Expression	[88]
HOMER1	OTWFD3SI	Strong	Biomarker	[89]
HOXB7	OTC7WYU8	Strong	Altered Expression	[90]
ID3	OTUULW5Z	Strong	Biomarker	[91]
IDH2	OTTQA4PB	Strong	Biomarker	[92]
ITGA3	OTBCH21D	Strong	Biomarker	[93]
KLHL2	OT1NG8V7	Strong	Biomarker	[94]
LRRFIP1	OTN7XAUD	Strong	Biomarker	[95]
MACC1	OTV3DLX0	Strong	Altered Expression	[96]
MAGI1	OTMV4ASV	Strong	Genetic Variation	[27]
MAPK6	OTDDNF3Q	Strong	Biomarker	[44]
MEGF8	OT5G38CH	Strong	Altered Expression	[97]
MEST	OT8Q4U8Y	Strong	Genetic Variation	[98]
MFAP5	OT46VXSG	Strong	Biomarker	[99]
MOB1A	OTSPBZ4Z	Strong	Biomarker	[100]
MOB4	OTOQRMAS	Strong	Biomarker	[100]
MPC1	OT6DYFUO	Strong	Biomarker	[101]
MUC13	OTWKS9MF	Strong	Altered Expression	[102]
MUC5B	OTPW6K5C	Strong	Biomarker	[24]
MUC6	OTPVL723	Strong	Biomarker	[31]
NEUROG1	OTMJZP9G	Strong	Biomarker	[103]
NRDC	OTWBBCXO	Strong	Biomarker	[104]
NSD2	OTQ6SW4R	Strong	Altered Expression	[105]
NUMB	OTMB586Q	Strong	Biomarker	[106]
PAX1	OT0Y3MIM	Strong	Posttranslational Modification	[107]
PDZK1IP1	OTWA6M5K	Strong	Altered Expression	[80]
PFKP	OTFP7AA8	Strong	Altered Expression	[108]
PPA1	OTHZK1QB	Strong	Biomarker	[109]
PPFIBP2	OTXQO55Y	Strong	Biomarker	[44]
PPHLN1	OTWG1WIH	Strong	Genetic Variation	[25]
PRDM5	OTU1GB68	Strong	Biomarker	[110]
PRKACB	OT6RMDCE	Strong	Genetic Variation	[111]
RAB1A	OTKPHRD0	Strong	Biomarker	[112]
RAD51AP1	OTXM7UTD	Strong	Biomarker	[113]
RCOR3	OT5LATME	Strong	Altered Expression	[114]
RNF2	OTFPLOIN	Strong	Genetic Variation	[27]
RPL41	OTFW5IFO	Strong	Biomarker	[80]
RPS4X	OTIH80EK	Strong	Altered Expression	[115]
S100A7	OTJFVJRF	Strong	Biomarker	[116]
SCAF11	OTX59D0X	Strong	Altered Expression	[84]
SGMS1	OTZQE7PW	Strong	Biomarker	[100]
SHMT2	OT5NCAZN	Strong	Biomarker	[117]
SLBP	OTVYYQRT	Strong	Biomarker	[73]
SMAD4	OTWQWCKG	Strong	Altered Expression	[118]
SSX4	OT0E4H2D	Strong	Biomarker	[119]
STAM2	OT9OBWPH	Strong	Biomarker	[73]
TFDP1	OT6RZ7VT	Strong	Biomarker	[120]
TRAF4	OTJLRVMC	Strong	Altered Expression	[121]
TRIM44	OT0B1T2B	Strong	Altered Expression	[122]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 214801.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT03633773) Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma
• [4] Application of mesothelin immunostaining in tumor diagnosis.Am J Surg Pathol. 2003 Nov;27(11):1418-28. doi: 10.1097/00000478-200311000-00003.
• [5] Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice.Cancer Res. 2006 Jul 1;66(13):6622-7. doi: 10.1158/0008-5472.CAN-05-4609.
• [6] Genomic spectra of biliary tract cancer.Nat Genet. 2015 Sep;47(9):1003-10. doi: 10.1038/ng.3375. Epub 2015 Aug 10.
• [7] Sodium iodide symporter is expressed at the preneoplastic stages of liver carcinogenesis and in human cholangiocarcinoma.Gastroenterology. 2007 Apr;132(4):1495-503. doi: 10.1053/j.gastro.2007.01.044. Epub 2007 Jan 26.
• [8] The cells and conductance mediating cholinergic neurotransmission in the murine proximal stomach.J Physiol. 2018 May 1;596(9):1549-1574. doi: 10.1113/JP275478. Epub 2018 Mar 23.
• [9] Response Evaluation Criteria in Cancer of the Liver version5 (RECICL 2019 revised version).Hepatol Res. 2019 Sep;49(9):981-989. doi: 10.1111/hepr.13394. Epub 2019 Jul 25.
• [10] Block of NF-kB signaling accelerates MYC-driven hepatocellular carcinogenesis and modifies the tumor phenotype towards combined hepatocellular cholangiocarcinoma.Cancer Lett. 2019 Aug 28;458:113-122. doi: 10.1016/j.canlet.2019.05.023. Epub 2019 May 22.
• [11] Improving pathological early diagnosis and differential biomarker value for hepatocellular carcinoma via RNAscope technology.Hepatol Int. 2020 Jan;14(1):96-104. doi: 10.1007/s12072-019-10006-z. Epub 2019 Dec 12.
• [12] Combined hepatocellular-cholangiocarcinoma: An analysis of clinicopathological characteristics after surgery.Medicine (Baltimore). 2019 Sep;98(38):e17102. doi: 10.1097/MD.0000000000017102.
• [13] Characterization and prognostic significance of mortalin, Bcl-2 and Bax in intrahepatic cholangiocarcinoma.Oncol Lett. 2018 Feb;15(2):2161-2168. doi: 10.3892/ol.2017.7570. Epub 2017 Dec 8.
• [14] Combination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinoma.PLoS One. 2017 Feb 6;12(2):e0170078. doi: 10.1371/journal.pone.0170078. eCollection 2017.
• [15] miR-424-5p represses the metastasis and invasion of intrahepatic cholangiocarcinoma by targeting ARK5.Int J Biol Sci. 2019 Jun 4;15(8):1591-1599. doi: 10.7150/ijbs.34113. eCollection 2019.
• [16] Human papillomavirus genotype distribution in high grade cervical lesions (CIN 2/3) in France: EDITH study.Int J Cancer. 2008 Jan 15;122(2):424-7. doi: 10.1002/ijc.23093.
• [17] Analysis of cytosine-adenine repeats in P1 promoter region of IGF-1 gene in peripheral blood cells and cervical tissue samples of females with cervical intraepithelial lesions and squamous cervical cancer.Mol Med Rep. 2015 Feb;11(2):766-74. doi: 10.3892/mmr.2014.2916. Epub 2014 Nov 10.
• [18] Inducible liver-specific overexpression of gankyrin in zebrafish results in spontaneous intrahepatic cholangiocarcinoma and hepatocellular carcinoma formation.Biochem Biophys Res Commun. 2017 Aug 26;490(3):1052-1058. doi: 10.1016/j.bbrc.2017.06.164. Epub 2017 Jun 28.
• [19] PTK7 is a novel oncogenic target for esophageal squamous cell carcinoma.World J Surg Oncol. 2017 May 25;15(1):105. doi: 10.1186/s12957-017-1172-x.
• [20] Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations.Oncotarget. 2016 Apr 26;7(17):23825-36. doi: 10.18632/oncotarget.8183.
• [21] Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma.Liver Int. 2018 Jan;38(1):113-124. doi: 10.1111/liv.13492. Epub 2017 Jul 10.
• [22] MicroRNA-101 inhibits the migration and invasion of intrahepatic cholangiocarcinoma cells via direct suppression of vascular endothelial growth factor-C.Mol Med Rep. 2015 Nov;12(5):7079-85. doi: 10.3892/mmr.2015.4239. Epub 2015 Aug 21.
• [23] Radiological features and outcomes ofcombined hepatocellular-cholangiocarcinoma inpatients undergoingsurgical resection.J Formos Med Assoc. 2020 Jan;119(1 Pt 1):125-133. doi: 10.1016/j.jfma.2019.02.012. Epub 2019 Mar 12.
• [24] Annexin A10 optimally differentiates between intrahepatic cholangiocarcinoma and hepatic metastases of pancreatic ductal adenocarcinoma: a comparative study of immunohistochemical markers and panels.Virchows Arch. 2017 May;470(5):537-543. doi: 10.1007/s00428-017-2114-2. Epub 2017 Mar 29.
• [25] Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma.Nat Commun. 2015 Jan 22;6:6087. doi: 10.1038/ncomms7087.
• [26] Immunization with aspartate--hydroxylase-loaded dendritic cells produces antitumor effects in a rat model of intrahepatic cholangiocarcinoma.Hepatology. 2012 Jan;55(1):86-97. doi: 10.1002/hep.24629.
• [27] Prognostic role of BAP-1 and PBRM-1 expression in intrahepatic cholangiocarcinoma.Virchows Arch. 2019 Jan;474(1):29-37. doi: 10.1007/s00428-018-2478-y. Epub 2018 Oct 30.
• [28] Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma.Dig Liver Dis. 2019 Sep;51(9):1337-1343. doi: 10.1016/j.dld.2019.03.019. Epub 2019 Apr 27.
• [29] Clinical Characteristics and Prognostic Factors of Patients with Intrahepatic Cholangiocarcinoma with Fever: A Propensity Score Matching Analysis.Oncologist. 2019 Jul;24(7):997-1007. doi: 10.1634/theoncologist.2018-0268. Epub 2019 Mar 25.
• [30] EVI1 expression is associated with aggressive behavior in intrahepatic cholangiocarcinoma.Virchows Arch. 2019 Jan;474(1):39-46. doi: 10.1007/s00428-018-2476-0. Epub 2018 Oct 23.
• [31] Mucinous intrahepatic cholangiocarcinoma: a distinct variant.Hum Pathol. 2018 Aug;78:131-137. doi: 10.1016/j.humpath.2018.04.010. Epub 2018 Apr 23.
• [32] Gallbladder cancer harboring ERBB2 mutation on the primary and metastatic site: A case report.World J Gastrointest Oncol. 2019 Sep 15;11(9):761-767. doi: 10.4251/wjgo.v11.i9.761.
• [33] Fatty acid-binding protein 5 promotes cell proliferation and invasion in human intrahepatic cholangiocarcinoma.Oncol Rep. 2012 Oct;28(4):1283-92. doi: 10.3892/or.2012.1922. Epub 2012 Jul 19.
• [34] Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.Br J Cancer. 2019 Jan;120(2):165-171. doi: 10.1038/s41416-018-0334-0. Epub 2018 Nov 13.
• [35] Multiplexed gene expression profiling identifies the FGFR4 pathway as a novel biomarker in intrahepatic cholangiocarcinoma.Oncotarget. 2017 Jun 13;8(24):38592-38601. doi: 10.18632/oncotarget.16951.
• [36] New observation of sialuria prompts detection of liver tumor in previously reported patient.Mol Genet Metab. 2016 Jun;118(2):92-9. doi: 10.1016/j.ymgme.2016.04.004. Epub 2016 Apr 16.
• [37] Decreased expression of HDAC8 indicates poor prognosis in patients with intrahepatic cholangiocarcinoma.Hepatobiliary Pancreat Dis Int. 2019 Oct;18(5):464-470. doi: 10.1016/j.hbpd.2019.07.006. Epub 2019 Jul 24.
• [38] Overexpression of interleukin-35 in intrahepatic cholangiocarcinoma is a prognostic indicator after curative resection.Cancer Sci. 2018 Apr;109(4):1195-1206. doi: 10.1111/cas.13535. Epub 2018 Mar 25.
• [39] IMP3 expression is associated with poor outcome and epigenetic deregulation in intrahepatic cholangiocarcinoma.Hum Pathol. 2014 Jun;45(6):1184-91. doi: 10.1016/j.humpath.2014.01.016. Epub 2014 Feb 6.
• [40] Intrahepatic cholangiocarcinoma after Fontan procedure in an adult with visceral heterotaxy.Pathol Res Pract. 2018 Jun;214(6):914-918. doi: 10.1016/j.prp.2018.03.016. Epub 2018 Mar 15.
• [41] Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.Biochim Biophys Acta Mol Basis Dis. 2018 Jun;1864(6 Pt B):2360-2368. doi: 10.1016/j.bbadis.2018.01.027. Epub 2018 Feb 1.
• [42] Implication of HLA-C and KIR alleles in human papillomavirus infection and associated cervical lesions.Viral Immunol. 2014 Nov;27(9):468-70. doi: 10.1089/vim.2014.0017. Epub 2014 Sep 4.
• [43] Keratin 19-expressing hepatocellular carcinoma and small-duct type intrahepatic cholangiocarcinoma show a similar postoperative clinical course but have distinct genetic features.Histopathology. 2019 Sep;75(3):385-393. doi: 10.1111/his.13884. Epub 2019 Jul 16.
• [44] Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.J Hematol Oncol. 2017 Feb 28;10(1):59. doi: 10.1186/s13045-017-0424-0.
• [45] Blocking of the EGFR-STAT3 signaling pathway through afatinib treatment inhibited the intrahepatic cholangiocarcinoma.Exp Ther Med. 2018 Jun;15(6):4995-5000. doi: 10.3892/etm.2018.6038. Epub 2018 Apr 5.
• [46] Reduced levels of N'-methyl-2-pyridone-5-carboxamide and lysophosphatidylcholine 16:0 in the serum of patients with intrahepatic cholangiocarcinoma, and the correlation with recurrence-free survival.Oncotarget. 2017 Nov 22;8(68):112598-112609. doi: 10.18632/oncotarget.22607. eCollection 2017 Dec 22.
• [47] Tumor-derived trypsin enhances proliferation of intrahepatic cholangiocarcinoma cells by activating protease-activated receptor-2.Int J Oncol. 2010 Apr;36(4):793-800. doi: 10.3892/ijo_00000555.
• [48] Combination of Kras activation and PTEN deletion contributes to murine hepatopancreatic ductal malignancy.Cancer Lett. 2018 May 1;421:161-169. doi: 10.1016/j.canlet.2018.02.017. Epub 2018 Feb 13.
• [49] Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AK... Oncotarget. 2016 Nov 15;7(46):75210-75220.
• [50] MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN.Oncotarget. 2015 Mar 20;6(8):5932-46. doi: 10.18632/oncotarget.3465.
• [51] RPB5-Mediating Protein Promotes Cholangiocarcinoma Tumorigenesis and Drug Resistance by Competing With NRF2 for KEAP1 Binding.Hepatology. 2020 Jun;71(6):2005-2022. doi: 10.1002/hep.30962. Epub 2020 Feb 20.
• [52] Reg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ductal adenocarcinoma.Oncotarget. 2016 Nov 22;7(47):77838-77853. doi: 10.18632/oncotarget.12834.
• [53] Ring finger protein 43 expression is associated with genetic alteration status and poor prognosis among patients with intrahepatic cholangiocarcinoma.Hum Pathol. 2016 Jun;52:47-54. doi: 10.1016/j.humpath.2015.12.027. Epub 2016 Feb 1.
• [54] Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments.Eur J Cancer. 2019 Jan;106:160-170. doi: 10.1016/j.ejca.2018.11.005. Epub 2018 Dec 5.
• [55] Depletion of STYK1 inhibits intrahepatic cholangiocarcinoma development both in vitro and in vivo.Tumour Biol. 2016 Oct;37(10):14173-14181. doi: 10.1007/s13277-016-5188-6. Epub 2016 Aug 19.
• [56] CRISPR-SONIC: targeted somatic oncogene knock-in enables rapid in vivo cancer modeling.Genome Med. 2019 Apr 16;11(1):21. doi: 10.1186/s13073-019-0627-9.
• [57] Ubiquitin-specific protease 14 expression associated with intrahepatic cholangiocarcinoma cell differentiation.Asian Pac J Cancer Prev. 2011;12(3):775-9.
• [58] LncRNA TUG1 sponges miR-145 to promote cancer progression and regulate glutamine metabolism via Sirt3/GDH axis.Oncotarget. 2017 Oct 19;8(69):113650-113661. doi: 10.18632/oncotarget.21922. eCollection 2017 Dec 26.
• [59] Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma.Hepatology. 2006 Oct;44(4):1025-38. doi: 10.1002/hep.21330.
• [60] Malic enzyme 1 is a potential marker of combined hepatocellular cholangiocarcinoma, subtype with stem-cell features, intermediate-cell type.Hepatol Res. 2019 Sep;49(9):1066-1075. doi: 10.1111/hepr.13365. Epub 2019 Jun 18.
• [61] Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma.Nat Commun. 2018 Mar 1;9(1):894. doi: 10.1038/s41467-018-03276-y.
• [62] H2A.Z regulates tumorigenesis, metastasis and sensitivity to cisplatin in intrahepatic cholangiocarcinoma.Int J Oncol. 2018 Apr;52(4):1235-1245. doi: 10.3892/ijo.2018.4292. Epub 2018 Feb 28.
• [63] Exome sequencing of liver fluke-associated cholangiocarcinoma.Nat Genet. 2012 May 6;44(6):690-3. doi: 10.1038/ng.2273.
• [64] Differentiation of hypervascular primary hepatic tumors showing hepatobiliary hypointensity on gadoxetic acid-enhanced magnetic resonance imaging.Abdom Radiol (NY). 2019 Sep;44(9):3115-3126. doi: 10.1007/s00261-019-02068-2.
• [65] [Corrigendum] CHD1L is associated with poor survival and promotes the proliferation and metastasis of intrahepatic cholangiocarcinoma.Oncol Rep. 2019 Oct;42(4):1631. doi: 10.3892/or.2019.7262. Epub 2019 Aug 5.
• [66] Prognostic significance of CXCL5 expression in cancer patients: a meta-analysis.Cancer Cell Int. 2018 May 2;18:68. doi: 10.1186/s12935-018-0562-7. eCollection 2018.
• [67] PTPN3 acts as a tumor suppressor and boosts TGF- signaling independent of its phosphatase activity.EMBO J. 2019 Jul 15;38(14):e99945. doi: 10.15252/embj.201899945. Epub 2019 Jun 14.
• [68] S100A11 promotes cell proliferation via P38/MAPK signaling pathway in intrahepatic cholangiocarcinoma.Mol Carcinog. 2019 Jan;58(1):19-30. doi: 10.1002/mc.22903. Epub 2018 Oct 21.
• [69] Expression and prognostic value of soluble CD97 and its ligand CD55 in intrahepatic cholangiocarcinoma.Tumour Biol. 2017 Mar;39(3):1010428317694319. doi: 10.1177/1010428317694319.
• [70] RA190, a Proteasome Subunit ADRM1 Inhibitor, Suppresses Intrahepatic Cholangiocarcinoma by Inducing NF-KB-Mediated Cell Apoptosis.Cell Physiol Biochem. 2018;47(3):1152-1166. doi: 10.1159/000490210. Epub 2018 Jun 15.
• [71] Differential expression of anterior gradient protein 3 in intrahepatic cholangiocarcinoma and hepatocellular carcinoma.Exp Mol Pathol. 2014 Jun;96(3):375-81. doi: 10.1016/j.yexmp.2014.04.002. Epub 2014 Apr 18.
• [72] High Beclin-1 and ARID1A expression corelates with poor survival and high recurrence in intrahepatic cholangiocarcinoma: a histopathological retrospective study.BMC Cancer. 2019 Mar 8;19(1):213. doi: 10.1186/s12885-019-5429-3.
• [73] Differentiation between inflammatory myofibroblastic tumor and cholangiocarcinoma manifesting as target appearance on gadoxetic acid-enhanced MRI.Abdom Radiol (NY). 2019 Apr;44(4):1395-1406. doi: 10.1007/s00261-018-1847-y.
• [74] Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis.Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):114-23. doi: 10.1158/1055-9965.EPI-05-0323.
• [75] A chimeric antibody to L1 cell adhesion molecule shows therapeutic effect in an intrahepatic cholangiocarcinoma model.Exp Mol Med. 2012 Apr 30;44(4):293-302. doi: 10.3858/emm.2012.44.4.027.
• [76] Prognostic significance of Capn4 overexpression in intrahepatic cholangiocarcinoma.PLoS One. 2013;8(1):e54619. doi: 10.1371/journal.pone.0054619. Epub 2013 Jan 22.
• [77] CUL4A overexpression as an independent adverse prognosticator in intrahepatic cholangiocarcinoma.BMC Cancer. 2017 Jun 2;17(1):395. doi: 10.1186/s12885-017-3389-z.
• [78] DLEC1 methylation is associated with a better clinical outcome in patients with intrahepatic cholangiocarcinoma of the small duct subtype.Virchows Arch. 2019 Jul;475(1):49-58. doi: 10.1007/s00428-018-02511-7. Epub 2019 Jan 4.
• [79] The tumor-associated antigen, RCAS1, can be expressed in immune-mediated diseases as well as in carcinomas of biliary tract.J Hepatol. 2002 Jun;36(6):786-92. doi: 10.1016/s0168-8278(02)00066-1.
• [80] Overexpression of PDZK1IP1, EEF1A2 and RPL41 genes in intrahepatic cholangiocarcinoma.Mol Med Rep. 2016 Jun;13(6):4786-90. doi: 10.3892/mmr.2016.5110. Epub 2016 Apr 12.
• [81] EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.Chin J Cancer. 2016 Jul 28;35(1):70. doi: 10.1186/s40880-016-0133-z.
• [82] The clinical value of Fibulin-1 for prognosis and its prospective mechanism in intrahepatic cholangiocarcinoma.HPB (Oxford). 2019 Apr;21(4):499-507. doi: 10.1016/j.hpb.2018.09.002. Epub 2018 Sep 26.
• [83] Gab1 regulates proliferation and migration through the PI3K/Akt signaling pathway in intrahepatic cholangiocarcinoma.Tumour Biol. 2015 Nov;36(11):8367-77. doi: 10.1007/s13277-015-3590-0. Epub 2015 May 28.
• [84] MiR-590-3p suppresses epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma by inhibiting SIP1 expression.Oncotarget. 2017 May 23;8(21):34698-34708. doi: 10.18632/oncotarget.16150.
• [85] Up-regulation of PSF2, a member of the GINS multiprotein complex, in intrahepatic cholangiocarcinoma.Oncol Rep. 2005 Sep;14(3):701-6.
• [86] High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases.Mod Pathol. 2014 May;27(5):731-9. doi: 10.1038/modpathol.2013.194. Epub 2013 Nov 1.
• [87] A multi-organ cancer study of the classification performance using 2D and 3D image features in radiomics analysis.Phys Med Biol. 2019 Nov 4;64(21):215009. doi: 10.1088/1361-6560/ab489f.
• [88] HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.J Immunother Cancer. 2019 Mar 18;7(1):77. doi: 10.1186/s40425-019-0554-8.
• [89] Identification of Homer1 as a potential prognostic marker for intrahepatic cholangiocarcinoma.Asian Pac J Cancer Prev. 2014;15(7):3299-304. doi: 10.7314/apjcp.2014.15.7.3299.
• [90] Upregulated expression of HOXB7 in intrahepatic cholangiocarcinoma is associated with tumor cell metastasis and poor prognosis.Lab Invest. 2019 Jun;99(6):736-748. doi: 10.1038/s41374-018-0150-4. Epub 2019 Jan 21.
• [91] ID3 Promotes Stem Cell Features and Predicts Chemotherapeutic Response of Intrahepatic Cholangiocarcinoma.Hepatology. 2019 May;69(5):1995-2012. doi: 10.1002/hep.30404. Epub 2019 Mar 8.
• [92] Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic Cholangiocarcinoma.Hepatology. 2019 May;69(5):2091-2106. doi: 10.1002/hep.30493. Epub 2019 Feb 28.
• [93] High Expression of ITGA3 Promotes Proliferation and Cell Cycle Progression and Indicates Poor Prognosis in Intrahepatic Cholangiocarcinoma.Biomed Res Int. 2018 Feb 4;2018:2352139. doi: 10.1155/2018/2352139. eCollection 2018.
• [94] HRAS, EGFR, MET, and RON Genes Are Recurrently Activated by Provirus Insertion in Liver Tumors Induced by the Retrovirus Myeloblastosis-Associated Virus 2.J Virol. 2017 Sep 27;91(20):e00467-17. doi: 10.1128/JVI.00467-17. Print 2017 Oct 15.
• [95] Knockdown of Nedd8conjugating enzyme UBE2M suppresses the proliferation and induces the apoptosis of intrahepatic cholangiocarcinoma cells.Oncol Rep. 2019 Dec;42(6):2670-2679. doi: 10.3892/or.2019.7327. Epub 2019 Sep 20.
• [96] Metastasis-associated in colon cancer 1 is an independent prognostic biomarker for survival in Klatskin tumor patients.Hepatology. 2015 Sep;62(3):841-50. doi: 10.1002/hep.27885. Epub 2015 Jun 26.
• [97] Reduced selenium-binding protein 1 correlates with a poor prognosis in intrahepatic cholangiocarcinoma and promotes the cell epithelial-mesenchymal transition.Am J Transl Res. 2018 Nov 15;10(11):3567-3578. eCollection 2018.
• [98] PEG1/MEST and IGF2 DNA methylation in CIN and in cervical cancer.Clin Transl Oncol. 2014 Mar;16(3):266-72. doi: 10.1007/s12094-013-1067-4. Epub 2013 Jun 18.
• [99] MFAP5 facilitates the aggressiveness of intrahepatic Cholangiocarcinoma by activating the Notch1 signaling pathway.J Exp Clin Cancer Res. 2019 Nov 27;38(1):476. doi: 10.1186/s13046-019-1477-4.
• [100] Altered Expression of Hippo Signaling Pathway Molecules in Intrahepatic Cholangiocarcinoma.Oncology. 2017;93(1):67-74. doi: 10.1159/000463390. Epub 2017 Apr 28.
• [101] Mitochondrial pyruvate carrier modulates the epithelial-mesenchymal transition in cholangiocarcinoma.Oncol Rep. 2018 Mar;39(3):1276-1282. doi: 10.3892/or.2017.6172. Epub 2017 Dec 20.
• [102] MUC13 promotes intrahepatic cholangiocarcinoma progression viaEGFR/PI3K/AKT pathways.J Hepatol. 2020 Apr;72(4):761-773. doi: 10.1016/j.jhep.2019.11.021. Epub 2019 Dec 16.
• [103] Methylation profiles of multiple CpG island loci in extrahepatic cholangiocarcinoma versus those of intrahepatic cholangiocarcinomas.Arch Pathol Lab Med. 2007 Jun;131(6):923-30. doi: 10.5858/2007-131-923-MPOMCI.
• [104] Serum Nardilysin, a Surrogate Marker for Epithelial-Mesenchymal Transition, Predicts Prognosis of Intrahepatic Cholangiocarcinoma after Surgical Resection.Clin Cancer Res. 2019 Jan 15;25(2):619-628. doi: 10.1158/1078-0432.CCR-18-0124. Epub 2018 Oct 23.
• [105] NSD2 inhibition suppresses metastasis in cervical cancer by promoting TGF-/TGF-RI/SMADs signaling.Biochem Biophys Res Commun. 2019 Nov 12;519(3):489-496. doi: 10.1016/j.bbrc.2019.08.020. Epub 2019 Sep 14.
• [106] Loss of nuclear NOTCH1, but not its negative regulator NUMB, is an independent predictor of cervical malignancy.Oncotarget. 2018 Apr 10;9(27):18916-18928. doi: 10.18632/oncotarget.24828. eCollection 2018 Apr 10.
• [107] Association between dense PAX1 promoter methylation and HPV16 infection in cervical squamous epithelial neoplasms of Xin Jiang Uyghur and Han women.Gene. 2020 Jan 10;723:144142. doi: 10.1016/j.gene.2019.144142. Epub 2019 Oct 4.
• [108] Mutant IDH1 confers resistance to energy stress in normal biliary cells through PFKP-induced aerobic glycolysis and AMPK activation.Sci Rep. 2019 Dec 11;9(1):18859. doi: 10.1038/s41598-019-55211-w.
• [109] Pyrophosphatase 1 expression is associated with future recurrence and overall survival in Chinese patients with intrahepatic cholangiocarcinoma.Oncol Lett. 2018 May;15(5):8095-8101. doi: 10.3892/ol.2018.8278. Epub 2018 Mar 15.
• [110] Necroptosis microenvironment directs lineage commitment in liver cancer.Nature. 2018 Oct;562(7725):69-75. doi: 10.1038/s41586-018-0519-y. Epub 2018 Sep 12.
• [111] FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma.Cancer Treat Rev. 2019 Aug;78:1-7. doi: 10.1016/j.ctrv.2019.06.003. Epub 2019 Jun 22.
• [112] Hypoxia-mediated miR-212-3p downregulation enhances progression of intrahepatic cholangiocarcinoma through upregulation of Rab1a.Cancer Biol Ther. 2018;19(11):984-993. doi: 10.1080/15384047.2018.1456608. Epub 2018 May 14.
• [113] Enhanced expression of RAD51 associating protein-1 is involved in the growth of intrahepatic cholangiocarcinoma cells.Clin Cancer Res. 2008 Mar 1;14(5):1333-9. doi: 10.1158/1078-0432.CCR-07-1381.
• [114] Integrated mRNA and lncRNA expression profiling for exploring metastatic biomarkers of human intrahepatic cholangiocarcinoma.Am J Cancer Res. 2017 Mar 1;7(3):688-699. eCollection 2017.
• [115] Overexpression of the X-linked ribosomal protein S4 predicts poor prognosis in patients with intrahepatic cholangiocarcinoma.Oncol Lett. 2017 Jul;14(1):41-46. doi: 10.3892/ol.2017.6137. Epub 2017 May 8.
• [116] MicroRNA-26b-5p regulates cell proliferation, invasion and metastasis in human intrahepatic cholangiocarcinoma by targeting S100A7.Oncol Lett. 2018 Jan;15(1):386-392. doi: 10.3892/ol.2017.7331. Epub 2017 Nov 2.
• [117] SHMT2 Overexpression Predicts Poor Prognosis in Intrahepatic Cholangiocarcinoma.Gastroenterol Res Pract. 2018 Aug 28;2018:4369253. doi: 10.1155/2018/4369253. eCollection 2018.
• [118] Histological and molecular characterization of intrahepatic bile duct cancers suggests an expanded definition of perihilar cholangiocarcinoma.HPB (Oxford). 2019 Feb;21(2):226-234. doi: 10.1016/j.hpb.2018.07.021. Epub 2018 Aug 28.
• [119] Expression of cancer-testis antigen (CTA) genes in intrahepatic cholangiocarcinoma.Ann Surg Oncol. 2004 Oct;11(10):934-40. doi: 10.1245/ASO.2004.01.029.
• [120] Recurrent Amplification at 13q34 Targets at CUL4A, IRS2, and TFDP1 As an Independent Adverse Prognosticator in Intrahepatic Cholangiocarcinoma.PLoS One. 2015 Dec 18;10(12):e0145388. doi: 10.1371/journal.pone.0145388. eCollection 2015.
• [121] Role of the overexpression of TRAF4 in predicting the prognosis of intrahepatic cholangiocarcinoma.Int J Oncol. 2018 Jul;53(1):286-296. doi: 10.3892/ijo.2018.4383. Epub 2018 Apr 26.
• [122] Elevated TRIM44 promotes intrahepatic cholangiocarcinoma progression by inducing cell EMT via MAPK signaling.Cancer Med. 2018 Mar;7(3):796-808. doi: 10.1002/cam4.1313. Epub 2018 Feb 15.